EP2492688A1 — Molecular biomarkers for predicting response to antitumor treatment in lung cancer
Assigned to Pangaea Biotech SL · Expires 2012-08-29 · 14y expired
What this patent protects
The invention relates to a method for predicting the response to the treatment with an antitumor agent of a patient suffering lung cancer based on the expression levels in a sample of said patient of the AEG-1 gene or of the combination of the AEG-1 and BRCA1 genes wherein low ex…
USPTO Abstract
The invention relates to a method for predicting the response to the treatment with an antitumor agent of a patient suffering lung cancer based on the expression levels in a sample of said patient of the AEG-1 gene or of the combination of the AEG-1 and BRCA1 genes wherein low expression levels of AEG-1 or low expression levels of AEG-1 and BRCA1 are indicative of a positive response of the patient to said antitumor agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.